폐렴 검사 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The Pneumonia Testing Market size is estimated at USD 1.97 billion in 2024, and is expected to reach USD 2.75 billion by 2029, growing at a CAGR of 6.93% during the forecast period (2024-2029).

Pneumonia testing market is growing at good rate as pneumonia is a life-threatening disease wherein testing helps the people to know in advance and further, they can be cured quickly. The major factor attributing to the growth of the market are rise in adoption of POC testing and development in the field of nucleic acid detection. Moreover, the awareness level is increasing day by day which results in early diagnosis, hence promoting the growth of pneumonia testing market.

In addition, pneumonia is found to be the major cause of death in children. For instance, in 2018 according to UNICEF, about 800000 children died due to pneumonia. Also, these diseases are more prevalent in South Asia and African countries. However, due to the limited detection capability and accuracy, the market is expected to be hampered to a certain extent.

Pneumonia Testing Market Trends

Point of Care Testing Segment is Expected to Contribute Major Market Share in the Pneumonia Testing Market

• POC testing is a revolutionary technology which is currently an ideal technique for detecting pneumonia. The growing adoption of POC testing is attributed to higher efficiency, increasing cases of pneumonia and the rapid test results due to which it is highly preferable.
• Therefore with the high prevalence of chronic diseases in large customer base adopting the cost-effective and immediate diagnostic tests, is propelling the point of care testing. The advantages of POC test to render rapid and accurate results helps in promoting the patient-centred healthcare at bedside settings which further result in the adoption of point of care testing and thereby promoting the growth of pneumonia testing market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global Pneumonia Testing due to increasing geriatric population region. For instance, according to Centers for Disease Control and Prevention pneumonia is an eighth leading cause for mortality in the United States which further lead to increased awareness about the disease and further drive the pneumonia testing market.

There are also rising product approval and increasing product launches that are driving the overall market in this region. For instance, BioMerieux has received FDA Clearance for BioFire's FilmArray Respiratory Panel 2 (RP2). Furthermore, with the increasing healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Pneumonia Testing Industry Overview

Pneumonia Testing Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific, Hologic, Inc, Meridian Bioscience, Quidel Corporation, BD and Curetis.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rise in Popularity of POC Testing
  • 4.2.2 Surge in Awareness Towards Early Diagnosis
  • 4.2.3 Increase in Government Expenditure on Healthcare
• 4.3 Market Restraints
  • 4.3.1 Limited Detection Capability and Accuracy
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Product Type
  • 5.1.1 Consumable
  • 5.1.2 Analyzer
• 5.2 By Method Type
  • 5.2.1 Immunodiagnostic
  • 5.2.2 Molecular Diagnostic
  • 5.2.3 Point-of-Care (POC) Testing
• 5.3 By Technology
  • 5.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
  • 5.3.2 Immunofluroscence
  • 5.3.3 Immunohistochemistry (IHC)
  • 5.3.4 Polymerase Chain Reaction (PCR)
  • 5.3.5 Others
• 5.4 By End-user
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Centers
  • 5.4.3 Others
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle-East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle-East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abbott
  • 6.1.2 Bio-Rad Laboratories, Inc.
  • 6.1.3 BioMerieux SA
  • 6.1.4 Becton, Dickinson and Company
  • 6.1.5 Curetis
  • 6.1.6 Hologic Inc.
  • 6.1.7 Meridian Bioscience
  • 6.1.8 Thermo Fisher Scientific
  • 6.1.9 Quidel Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS